Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
New England Journal of Medicine2012Vol. 367(25), pp. 2407–2418
Citations Over TimeTop 1% of 2012 papers
Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham, Eiji Higashihara, Ronald D. Perrone, Holly B. Krasa, John Ouyang, Frank S. Czerwiec
Abstract
Tolvaptan, as compared with placebo, slowed the increase in total kidney volume and the decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, owing to adverse events. (Funded by Otsuka Pharmaceuticals and Otsuka Pharmaceutical Development and Commercialization; TEMPO 3:4 ClinicalTrials.gov number, NCT00428948.).
Related Papers
- → Long-Term Safety of Tolvaptan in ADPKD(2020)4 cited
- → Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea(2018)1 cited
- → SUN-370 TOLVAPTAN USE IN YOUNG ADULTS WITH RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE(2020)1 cited
- → Transcriptomic and metabolic profiling of Tolvaptan treated Autosomal dominant polycystic kidney disease (ADPKD) patient(2022)
- → #5882 BENEFIT OF LONG-TERM TOLVAPTAN ADMINISTRATION ON KIDNEY DISEASE PROGRESSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A SINGLE-CENTRE EXPERIENCE(2023)